MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
Go back to MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia| (NASDAQ: MGTX) | Delayed: 11.48 +0.16 (1.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.32 | 52 Week High | $ | |||
| Open | $11.48 | 52 Week Low | $ | |||
| Day High | $11.81 | P/E | N/A | |||
| Day Low | $11.18 | EPS | $ | |||
| Volume | 1,292,750 | |||||
